Focus Partners Advisor Solutions LLC Boosts Stake in Tenet Healthcare Corporation $THC

Focus Partners Advisor Solutions LLC grew its position in Tenet Healthcare Corporation (NYSE:THC) by 104.9% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 7,569 shares of the company’s stock after purchasing an additional 3,875 shares during the period. Focus Partners Advisor Solutions LLC’s holdings in Tenet Healthcare were worth $1,496,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Norges Bank acquired a new stake in shares of Tenet Healthcare in the second quarter worth $206,981,000. Boston Partners increased its holdings in Tenet Healthcare by 95.0% in the 2nd quarter. Boston Partners now owns 2,267,142 shares of the company’s stock valued at $398,949,000 after purchasing an additional 1,104,500 shares in the last quarter. Alliancebernstein L.P. lifted its stake in shares of Tenet Healthcare by 375.7% during the second quarter. Alliancebernstein L.P. now owns 790,254 shares of the company’s stock worth $139,085,000 after purchasing an additional 624,125 shares in the last quarter. Holocene Advisors LP purchased a new stake in shares of Tenet Healthcare in the second quarter worth about $102,855,000. Finally, WCM Investment Management LLC raised its holdings in shares of Tenet Healthcare by 244.4% during the 3rd quarter. WCM Investment Management LLC now owns 510,224 shares of the company’s stock valued at $102,657,000 after buying an additional 362,083 shares during the period. 95.44% of the stock is owned by institutional investors and hedge funds.

Tenet Healthcare Trading Down 1.6%

Shares of NYSE THC opened at $240.88 on Friday. The stock has a market capitalization of $20.95 billion, a P/E ratio of 15.55, a PEG ratio of 1.21 and a beta of 1.39. The stock’s 50 day moving average price is $209.41 and its two-hundred day moving average price is $201.66. The company has a quick ratio of 1.68, a current ratio of 1.76 and a debt-to-equity ratio of 2.18. Tenet Healthcare Corporation has a 52-week low of $109.82 and a 52-week high of $247.21.

Tenet Healthcare (NYSE:THC) last posted its quarterly earnings results on Wednesday, February 11th. The company reported $4.70 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.08 by $0.62. Tenet Healthcare had a return on equity of 26.33% and a net margin of 6.60%.The business had revenue of $5.53 billion for the quarter, compared to analyst estimates of $5.47 billion. During the same period in the prior year, the company posted $3.44 EPS. The business’s revenue was up 8.9% compared to the same quarter last year. Tenet Healthcare has set its FY 2026 guidance at 16.190-18.470 EPS. On average, analysts anticipate that Tenet Healthcare Corporation will post 12.24 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, Director Nadja West sold 2,178 shares of the stock in a transaction that occurred on Monday, December 15th. The stock was sold at an average price of $197.47, for a total transaction of $430,089.66. Following the sale, the director directly owned 28,480 shares in the company, valued at approximately $5,623,945.60. This represents a 7.10% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Thomas W. Arnst sold 24,000 shares of the business’s stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $234.04, for a total value of $5,616,960.00. Following the transaction, the executive vice president owned 8,012 shares of the company’s stock, valued at $1,875,128.48. This represents a 74.97% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 34,195 shares of company stock worth $7,912,606 over the last quarter. 0.81% of the stock is owned by company insiders.

Analysts Set New Price Targets

A number of research firms have recently commented on THC. Morgan Stanley reissued an “overweight” rating and set a $260.00 target price on shares of Tenet Healthcare in a research report on Thursday, February 12th. Royal Bank Of Canada upped their price objective on shares of Tenet Healthcare from $253.00 to $277.00 and gave the company an “outperform” rating in a research report on Thursday, February 12th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Tenet Healthcare in a research report on Wednesday. Wall Street Zen raised Tenet Healthcare from a “buy” rating to a “strong-buy” rating in a report on Sunday, March 1st. Finally, Leerink Partners upped their target price on Tenet Healthcare from $255.00 to $264.00 and gave the company an “outperform” rating in a research report on Friday, February 20th. One analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat, Tenet Healthcare has a consensus rating of “Moderate Buy” and an average target price of $247.67.

About Tenet Healthcare

Tenet Healthcare Corporation (NYSE: THC) is a diversified American healthcare services company that owns and operates acute care hospitals and a broad range of outpatient facilities. Its portfolio includes general acute-care hospitals, specialty hospitals, ambulatory surgery centers, urgent care and diagnostic imaging centers, and other ancillary service locations. Tenet’s operations are oriented around delivering inpatient and outpatient clinical care across multiple medical specialties, with an emphasis on surgical services, emergency care, and advanced diagnostics.

In addition to facility-based care, Tenet provides integrated services designed to support clinical operations and improve patient access and care coordination.